AstraZeneca: FDA Approves Self-Administered Fasenra Pen

Date : 10/04/2019 @ 6:43AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7275.0  -31.0 (-0.42%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca: FDA Approves Self-Administered Fasenra Pen

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Astrazeneca Charts.
   By Carlo Martuscelli 

AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration approved one of its respiratory medicines as a self-administered and pre-filled syringe called the Fasenra pen.

Fasenra, a treatment for severe eosinophilic asthma, can now be used by patients themselves as an injection administered once every eight weeks. The pharmaceutical company said that this allows for more convenient dosing at home.

Fasenra was already approved in the U.S., as well as Europe and Japan as a drug given by doctors.


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

October 04, 2019 02:28 ET (06:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191212 20:10:10